
Opinion|Videos|April 14, 2025
Evaluating Ruxolitinib In An 18-Month Retrospective Claims Analysis
Author(s)Gary M. Owens, MD , Lawrence Eichenfield, MD
Panelists discuss how an 18-month retrospective claims analysis evaluated ruxolitinib's real-world effectiveness in atopic dermatitis, demonstrating sustained disease control, reduced healthcare utilization, decreased steroid dependency, improved medication adherence, and consistent safety outcomes across diverse patient demographics and disease severities compared to conventional treatments.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
3
Brukinsa provides long-term disease control in chronic lymphocytic leukemia
4
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
5

























